<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999947</url>
  </required_header>
  <id_info>
    <org_study_id>P051067</org_study_id>
    <nct_id>NCT00999947</nct_id>
  </id_info>
  <brief_title>Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy</brief_title>
  <acronym>DVDA</acronym>
  <official_title>Genetic Study of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the genetic and phenotypic aspects of Arrhythmogenic&#xD;
      Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), and determine the impact of genetic&#xD;
      testing in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/ARVC), is an inherited&#xD;
      myocardial disease that predominantly affects the right ventricle (RV) and the estimated&#xD;
      prevalence in the general population ranges from 1 to 5 in 1000. It is characterized&#xD;
      histopathologically by fibro-fatty myocardial replacement and clinically by ventricular&#xD;
      arrhythmia that may lead to sudden death, especially in young people and athletes. Clinical&#xD;
      diagnosis is based on diagnostic criteria proposed by the International Task Force of the&#xD;
      European Society of Cardiology and International Society and Federation of Cardiology (Task&#xD;
      Force 1994), but is often difficult due to a broad spectrum of clinical features and a lond&#xD;
      period of concealed cardiac expression, with delayed diagnosis.&#xD;
&#xD;
      ARVC/D is familial in 30 to 50% and is typically transmitted as an autosomal dominant trait&#xD;
      with variable penetrance. In the past years, the identification of causative mutations in&#xD;
      plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2),&#xD;
      desmocollin-2 (DSC2) has fostered the view that ARVC/D is a disorder of the desmosome and&#xD;
      provided new insight into its pathogenesis.&#xD;
&#xD;
      The major recent advance in the molecular genetics of ARVD/C might lead to important clinical&#xD;
      impact through early and correct diagnosis in patients and relatives, and through potential&#xD;
      genotype-phenotype correlations. This key-issue requires first to clarify the optimal&#xD;
      molecular strategy, and its efficiency. Such a systematic, detailed and comprehensive&#xD;
      mutation screening study is not available until now.&#xD;
&#xD;
      Aim:&#xD;
&#xD;
      Study the genetic and phenotypic aspects of Arrhythmogenic Right Ventricular&#xD;
      Dysplasia/Cardiomyopathy (ARVD/C), and determine the impact of genetic testing in clinical&#xD;
      practice.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The study was approved by the Pitié-Salpétriêre Hospital ethical committee (CPPRB) and&#xD;
      written informed consent was obtained from all participating individuals, recruited in&#xD;
      France.&#xD;
&#xD;
      A cohort of 100 unrelated patients with ARVD/C will be recruited. Clinical evaluation will&#xD;
      include clinical history, family history, blood sample for DNA analysis 12-lead ECG,&#xD;
      signal-average ECG, 24-hour ambulatory ECG, transthoracic echocardiography, MRI and/or&#xD;
      radionuclide scintigraphy, and contrast angiography when possible. A clinical diagnosis of&#xD;
      ARVD/C is made according to the established European Society of Cardiology / International&#xD;
      Society and Federation of Cardiology Task Force major and minor criteria (Task Force 1994).&#xD;
&#xD;
      All available relatives will be proposed for enrollment in the study with blood sample for&#xD;
      DNA analysis and non invasive cardiac examination, including 12-lead ECG, signal-average ECG,&#xD;
      and transthoracic echocardiography.&#xD;
&#xD;
      Mutational analysis of the five genes encoding desmosomal genes will be performed in all&#xD;
      index cases (in plakoglobin, desmoplakin, plakophilin-2, desmoglein-2, desmocollin-2). When&#xD;
      mutations will be identified, available relatives will be analysed. In index cases without&#xD;
      desmosomal mutation, additional analyses will be performed according to a candidate gene&#xD;
      strategy and, when possible, through a genome wide approach and linkage analyses.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
      Determine the genetic origin in patients with ARVD/C whatever the familial context.&#xD;
&#xD;
      Determine a molecular strategy for routine genetic testing. Determine the impact of genetic&#xD;
      testing as a diagnostic test in patients and relatives.&#xD;
&#xD;
      Determine the impact of genetics as a prognostic tool, through phenotype-genotype analyses.&#xD;
&#xD;
      Determine the natural evolution of the disease in relatives, and the penetrance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the genetic origin in patients with ARVD/C whatever the familial context</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <enrollment type="Actual">351</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Dysplasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Unrelated patients with ARVD/C. A clinical diagnosis of ARVD/C is made according to the&#xD;
        established European Society of Cardiology / International Society and Federation of&#xD;
        Cardiology Task Force major and minor criteria (Task Force 1994)&#xD;
&#xD;
        + All available relatives will be proposed for enrollement in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with DVDA diagnostic confirmed&#xD;
&#xD;
          -  Acceptance even follow-up&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossible to understand the notice information about study&#xD;
&#xD;
          -  Not affiliated with social protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Charron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2009</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>genetics</keyword>
  <keyword>mutation screening</keyword>
  <keyword>phenotype-genotype analysis</keyword>
  <keyword>desmosomal genes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

